Immunocore announces transition of Chief Financial Officer
August 29 2024 - 6:00AM
Immunocore announces transition of Chief
Financial Officer
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 29 August 2024) Immunocore Holdings plc
(Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage
biotechnology company pioneering and delivering transformative
immunomodulating medicines to radically improve outcomes for
patients with cancer, infectious diseases and autoimmune
diseases, today announced that its Chief Financial Officer
(CFO) and Head of Strategy, Brian Di Donato, has informed the
Company of his plans to leave at the end of the year. Mr. Di Donato
has accepted the role of Chief Executive Officer at a private,
early-stage biotech headquartered in San Diego, California.
Immunocore will initiate a search for a new CFO.
Brian will remain as the Company’s CFO and Head of Strategy through
the end of 2024, to ensure a smooth transition.
“Brian has been an invaluable member of our team
for over four years, and his leadership was instrumental in the
success of our IPO. He built a successful Finance department and
leaves a proven team that will continue supporting the company
moving forward,” said Bahija Jallal, Chief Executive
Officer at Immunocore. “During his tenure, we have
successfully raised significant capital to invest in our innovative
platform and our rapidly growing clinical and research portfolio. I
am grateful for Brian’s many contributions and wish him continued
success in his next role as CEO.”
"I am proud of what we have accomplished at
Immunocore and honored to have worked with such a talented team
that led the Company to become a commercial-stage biotech company,
with the launch of the world’s first TCR therapy," said
Brian Di Donato, Chief Financial Officer at Immunocore.
"It has been a privilege to be part of the company's journey, and I
look forward to its continued success with the planned data
readouts of the three Phase 3 clinical trials and the expansion
into autoimmune diseases."
About Immunocore
Immunocore is a commercial-stage biotechnology
company pioneering the development of a novel class of TCR
bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including nine active clinical and pre-clinical
programs in oncology, infectious diseases, and autoimmune
diseases. The Company’s most advanced oncology TCR therapeutic,
KIMMTRAK has been approved for the treatment of
HLA-A*02:01-positive adult patients with unresectable or metastatic
uveal melanoma in the United States, European Union, Canada,
Australia, and the United Kingdom.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Words such as
“may”, “will”, “believe”, “expect”, “plan”, “anticipate” and
similar expressions (as well as other words or expressions
referencing future events or circumstances) are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release are
forward-looking statements. These statements include, but are not
limited to, statements regarding Immunocore’s timing and search for
a new Chief Financial Officer; continued development of
Immunocore’s clinical and research portfolio; and Immunocore’s
expectations regarding planned data readouts of three Phase 3
clinical trials and expansion into autoimmune diseases. Any
forward-looking statements are based on management’s current
expectations and beliefs of future events and are subject to a
number of risks and uncertainties that could cause actual events or
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements, many of which are
beyond the Company’s control. These risks and uncertainties
include, but are not limited to, the impact of worsening
macroeconomic conditions on the Company’s business, financial
position, strategy and anticipated milestones, including
Immunocore’s ability to conduct ongoing and planned clinical
trials; Immunocore’s ability to obtain a clinical supply of current
or future product candidates or commercial supply of KIMMTRAK or
any future approved products, including as a result of health
epidemics or pandemics, war in Ukraine, the conflict between Hamas
and Israel, or global geopolitical tension; Immunocore’s ability to
obtain and maintain regulatory approval of its product candidates,
including KIMMTRAK; Immunocore’s ability and plans in continuing to
establish and expand a commercial infrastructure and to
successfully launch, market and sell KIMMTRAK and any future
approved products; Immunocore’s ability to successfully expand the
approved indications for KIMMTRAK or obtain marketing approval for
KIMMTRAK in additional geographies in the future; the delay of any
current or planned clinical trials, whether due to patient
enrollment delays or otherwise; Immunocore’s ability to
successfully demonstrate the safety and efficacy of its product
candidates and gain approval of its product candidates on a timely
basis, if at all; competition with respect to market opportunities;
unexpected safety or efficacy data observed during preclinical
studies or clinical trials; actions of regulatory agencies, which
may affect the initiation, timing and progress of clinical trials
or future regulatory approval; Immunocore’s need for and ability to
obtain additional funding, on favorable terms or at all, including
as a result of worsening macroeconomic conditions, including
changes inflation and interest rates and unfavorable general market
conditions, and the impacts thereon of the war in Ukraine, the
conflict between Hamas and Israel, and global geopolitical tension;
Immunocore’s ability to obtain, maintain and enforce intellectual
property protection for KIMMTRAK or any of its product candidates
it or its collaborators are developing; and the success of
Immunocore’s current and future collaborations, partnerships or
licensing arrangements, including the risk that Immunocore may not
realize the anticipated benefits of its collaboration with Bristol
Myers Squibb. These and other risks and uncertainties are described
in greater detail in the section titled "Risk Factors" in
Immunocore’s filings with the Securities and Exchange Commission,
including Immunocore’s most recent Annual Report on Form 10-K for
the year ended December 31, 2023 filed with the Securities and
Exchange Commission on February 28, 2024, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company’s subsequent filings with the SEC. All information in this
press release is as of the date of the release, and the Company
undertakes no duty to update this information, except as required
by law.
Contact Information
Immunocore
Sébastien Desprez, Head of CommunicationsT: +44
(0) 7458030732E: sebastien.desprez@immunocore.comFollow on Twitter:
@Immunocore
Investor Relations
Clayton Robertson, Head of Investor RelationsT:
+1 (215) 384-4781E: ir@immunocore.com
Immunocore (NASDAQ:IMCR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Immunocore (NASDAQ:IMCR)
Historical Stock Chart
From Jan 2024 to Jan 2025
